
The medication tenofovir, or Viread, taken once a day may prevent HIV transmission among injection drug users, U.S. researchers say. Dr. Michael Martin of the Centers for Disease Control and Prevention in Atlanta said a randomized, phase III trial of injection drugs users in Bangkok found daily tenofovir reduced the risk of human immunodeficiency virus by nearly half compared with a placebo, MedPage Today reported. The study, published in The Lancet, showed daily tenofovir reduced HIV transmission in injecting drug users and it should be considered as an additional prevention method for people at high risk for HIV from infection. The researchers enrolled 2,413 volunteers ages 20-60 who were HIV-negative and reported injecting drugs within the previous 12 months -- from 17 drug-treatment clinics in Bangkok. Study participants were randomly assigned either tenofovir or placebo and followed for an average of four years. They were also offered condoms and methadone treatment and got monthly HIV testing, combined with risk-reduction and adherence counseling and blood safety tests every three months. Those in the trial who received the drug reduced HIV incidence by half, the study said.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor